.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG08_Ocrelizumab.Ocrelizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG08_Ocrelizumab.Ocrelizumab| name: | Ocrelizumab | |
| ATC code: | L04AG08 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 600 | mg |
| volume of distribution: | 3.11 | L |
| clearance: | 0.17 | L/day |
| other parameters in model implementation | ||
Ocrelizumab is a humanized monoclonal antibody targeting CD20-positive B-cells, used for the treatment of relapsing and primary progressive forms of multiple sclerosis (MS). It is approved by regulatory agencies including the FDA and EMA.
Population pharmacokinetic data in adult MS patients, both sexes, typically aged 18-55 years, with normal renal and hepatic function.